FDA OKs Genzyme Drug for Leukemia
U.S. regulators said they approved a new cancer drug from Genzyme Corp. for treating a type of childhood leukemia after other therapies have failed.
In a statement, the Food and Drug Administration said it approved the drug, Clolar, for treating patients ages 1 to 21 with cases of acute lymphocytic leukemia that have progressed after at least two previous cancer-fighting regimens.
Clolar was studied as a therapy for severe childhood cases of that illness as well as another blood cancer called acute myeloid leukemia. But a FDA advisory panel ruled this month that data were lacking on the benefits of Clolar therapy in patients with acute myeloid leukemia.
From Reuters
* Barr Pharmaceuticals Inc., the biggest U.S. maker of birth control pills, bought the U.S. rights to Nordette emergency contraceptive pills from King Pharmaceuticals Inc. for $12 million.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
